Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2605541 versus insulin glargine with mealtime insulin lispro in type 1 diabetes mellitus
2011-001253-82Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2011
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial in diabetes mellitus type 1 (T1D) comparing LY2605541 + insulin lispro with insulin glargine + insulin lispro (2 arms). Primary endpoint: Primary efficacy endpoint. Started Oct 2011; status: completed.
02
Drugs
insulin peglisproinsulin glargineinsulin lispro
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2011-001253-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001253-82.